Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis

Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;pii: S0168-8278(19):30343-5.

Publication Type:

Journal Article

Authors:

Borgia, Sergio M.; Dearden, J; Yoshida, EM.; et, al

Source:

J Hepatol, Volume pii: S0168-8278, Issue 19, p.30343-5 (2019)

Cited On:

Patients with Renal Impairment

Export Citation:

RIS Format

Top